Endo, Allergan to settle first opioid lawsuits - report - Breaking The News
Download our appPlay StoreApp Store

Endo, Allergan to settle first opioid lawsuits - report

Pharmaceutical companies Endo International Plc and Allergan Plc are nearing a settlement with two of the United States' counties in a landmark opioid crisis case, the Wall Street Journal reported. According to the sources familiar with the matter, the companies would pay $10 million and $5 million, respectively, in case the deal was reached.

Both firms would still be liable in hundreds of other cases in which they have been sued by other US local governments. Said settlements may not entirely eliminate Endo and Allergan from impending trial.

Thousands of states, counties, and cities within the US sued multiple drugmakers over their perceived role in the drug overdose epidemics in the country.

Related Stocks
Allergan ALLERGAN...
Endo INT. ENDO IN...
Related News
Roche's 2024 sales up 7% to 60.5B Swiss francs
F. Hoffmann-La Roche AG said on Thursday its annual sales in 2024 reached 60.5 billion Swiss francs, climbing 3% in Swiss francs and 7% at constant exchange rates (CER) from the same period a year earlier. Sales in the pharmaceuticals division grew 8% at CER to 46.2 billion Swiss francs, while diagnostics division sales rose 4% at CER year on year to 14.3 billion Swiss francs.In the year, net income dropped 19% at CER to 9.2 billion Swiss francs...
Roche's Q3 sales up 6% to 15.1B Swiss francs
Roche Group said on Wednesday that its sales stood at 15.1 billion Swiss francs in the third quarter of 2024, climbing 6% in Swiss francs and 9% at constant exchange rates from the same period a year earlier. Sales in the pharmaceuticals division grew 10% at constant exchange rates to 11.6 billion Swiss francs, while diagnostics division sales rose 6% at constant exchange rates year on year to 3.5 billion Swiss francs.For the first nine months of 2024, Roche's sales...
Eli Lilly appoints Lucas Montarce as CFO
Eli Lilly and Company announced in a press release on Monday that it is appointing Lucas Montarce as its new executive vice president and chief financial officer, effective immediately."I am committed to building on our strong financial foundation and helping drive continued success as we expand our global footprint and deliver long-term value to our stakeholders," Montarce stated and added that he was "honored" to take up this new position at the...
Viking Therapeutics soars 80% on weight loss drug news
Shares of Viking Therapeutics skyrocketed more than 80% in Tuesday's premarket trading after the biopharmaceutical company announced positive results from the phase 2 clinical of its weight loss drug VK2735. "Patients receiving weekly doses of VK2735 demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to 14.7% from baseline. Patients receiving VK2735 also demonstrated statistically significant reductions in...

Please observe our Terms of Use. The price information is time delayed to varying extents, but as a rule by 15 minutes or more, according to the regulations of the selected stock exchange and/or licensors and the type of securities.

© 2025 TeleTrader Software GmbH. All rights reserved

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.